Stryker Corp (SYK)
363.66
-0.18 (-0.05%)
Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients
The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including CooperCompanies (NASDAQCOO) and its peers.
Via StockStory · March 13, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · March 12, 2025

Discover 3 must-own investments for lifelong growth. From dividend stocks to a market-beating ETF, these picks offer stability, returns, and long-term wealth.
Via MarketBeat · March 10, 2025

Via Benzinga · March 3, 2025

Via Benzinga · February 21, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
Via StockStory · February 28, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
Via StockStory · February 25, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
Via StockStory · February 24, 2025

Via Benzinga · February 4, 2025

Via Benzinga · January 29, 2025

Healthcare company Baxter International (NYSEBAX)
will be reporting earnings tomorrow morning. Here’s what investors should know.
Via StockStory · February 19, 2025

Healthcare company Baxter International (NYSEBAX)
will be announcing earnings results tomorrow morning. Here’s what investors should know.
Via StockStory · February 12, 2025

Via Benzinga · February 11, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Via StockStory · February 10, 2025

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSEABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Via Benzinga · February 5, 2025

Medical technology company Stryker (NYSESYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its non-GAAP profit of $4.01 per share was 3.5% above analysts’ consensus estimates.
Via StockStory · January 31, 2025

Wall Street analysts upgraded Stryker Corp (NYSESYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025.
Via Benzinga · January 29, 2025

Via Benzinga · January 29, 2025

U.S. stock futures were mixed ahead of the crucial earnings from key U.S. technology companies and the Fed's expected pause on rate cuts.
Via Benzinga · January 29, 2025

Stryker stock dipped late Tuesday after the medtech company beat forecasts, but announced its plan to divest the U.S. spinal business.
Via Investor's Business Daily · January 28, 2025

Via Benzinga · January 29, 2025